Loading...
•
Jun 30, 2021
Akero Q2 2021 Earnings Report
Reported second quarter financial results for the period ending June 30, 2021.
Key Takeaways
Akero Therapeutics reported its second quarter financial results, highlighting the potential of efruxifermin (EFX) as a treatment for both pre-cirrhotic (F2/F3) and cirrhotic (F4) NASH. The company is set to initiate its second Phase 2b clinical trial in patients with late-stage cirrhotic NASH (F4).
Akero is developing transformational treatments for non-alcoholic steatohepatitis (NASH).
Efruxifermin (EFX) has the potential to be among the first investigational NASH therapies approved for treatment of both pre-cirrhotic (F2/F3) and cirrhotic (F4) NASH.
A second Phase 2b clinical trial will be initiated in patients with late-stage cirrhotic NASH (F4).
EFX is designed to offer convenient once-weekly subcutaneous dosing.